TechNavios analysts forecast the Global Lung Cancer Therapeutics market to grow at a CAGR of 13.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant growth of the Lung Cancer Therapeutics market in the US. The Global Lung Cancer Therapeutics market has also been witnessing an increase in the number of M&As. However, the adversative side effects of lung cancer therapeutic drugs could pose a challenge to the growth of this market.
TechNavios report, the Global Lung Cancer Therapeutics Market 2012-2016, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG.
The other vendors mentioned in the report are Ambit Biosciences Inc., ARIAD Pharmaceuticals Inc., Biogen Idec Inc., Cephalon Inc., Clavis Pharma ASA, Eisai Co. Ltd., ERYtech Pharma SA, Genmab A/S, Genzyme Corp., Pfizer Inc., Sunesis Pharmaceuticals Inc., Talon Therapeutics Inc., and Teva Pharmaceutical Industries Ltd.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Hoffmann-La Roche Ltd.
15.2 Eli Lilly and Co.
15.3 Sanofi S.A.
15.4 Bristol-Myers Squibb Co.
15.5 AstraZeneca plc
15.6 Novartis AG
15.7 GlaxoSmithKline plc
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Lung Cancer Therapeutics Market 2012â2016 (US$ billion)
Exhibit 2: Global Lung Cancer Therapeutics Market by Geographical Segmentation 2012
Exhibit 3: Global Lung Cancer Therapeutics Market by Vendor Segmentation 2012
Exhibit 4: Global Lung Cancer Therapeutics Market by Leading Drugs Segmentation 2012
Exhibit 5: Business Segmentation of Hoffmann-La Roche Ltd.
Exhibit 6: Business Segmentation of Eli Lilly and Co.
Exhibit 7: Business Segmentation of Sanofi S.A.
Exhibit 8: Business Segmentation of Bristol-Myers Squibb Co.
Exhibit 9: Business Segmentation of AstraZeneca plc
Exhibit 10: Business Segmentation of Novartis AG
Exhibit 11: Business Segmentation of GlaxoSmithKline plc